Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Crosses Below 200-Day Moving Average of $26.26

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Rating) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $26.26 and traded as low as $21.59. Agios Pharmaceuticals shares last traded at $21.90, with a volume of 477,277 shares.

Wall Street Analyst Weigh In

AGIO has been the topic of several research reports. SVB Leerink raised their price objective on Agios Pharmaceuticals to $33.00 and gave the stock a “market perform” rating in a report on Tuesday, May 17th. StockNews.com initiated coverage on Agios Pharmaceuticals in a report on Thursday, March 31st. They set a “sell” rating on the stock. Finally, The Goldman Sachs Group reduced their price objective on Agios Pharmaceuticals from $20.00 to $16.00 and set a “sell” rating on the stock in a report on Tuesday, May 24th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $50.57.

Agios Pharmaceuticals Trading Up 1.3 %

The firm has a market cap of $1.20 billion, a P/E ratio of -3.40 and a beta of 1.34. The firm has a 50-day simple moving average of $20.99 and a 200-day simple moving average of $26.26.

Agios Pharmaceuticals (NASDAQ:AGIO – Get Rating) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.85) by $0.11. The business had revenue of $0.83 million during the quarter, compared to analyst estimates of $2.71 million. During the same period in the previous year, the business earned ($1.31) EPS. Research analysts predict that Agios Pharmaceuticals, Inc. will post -7.05 earnings per share for the current fiscal year.

Institutional Trading of Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGIO. Point72 Hong Kong Ltd lifted its position in Agios Pharmaceuticals by 214.6% during the 4th quarter. Point72 Hong Kong Ltd now owns 1,513 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 1,032 shares during the period. Lazard Asset Management LLC raised its stake in shares of Agios Pharmaceuticals by 37.9% during the 1st quarter. Lazard Asset Management LLC now owns 2,930 shares of the biopharmaceutical company’s stock valued at $84,000 after buying an additional 805 shares during the last quarter. Envestnet Asset Management Inc. purchased a new position in shares of Agios Pharmaceuticals during the 1st quarter valued at about $230,000. E Fund Management Co. Ltd. purchased a new position in shares of Agios Pharmaceuticals during the 1st quarter valued at about $260,000. Finally, Connacht Asset Management LP raised its stake in shares of Agios Pharmaceuticals by 35.3% during the 1st quarter. Connacht Asset Management LP now owns 9,648 shares of the biopharmaceutical company’s stock valued at $281,000 after buying an additional 2,515 shares during the last quarter.

Agios Pharmaceuticals Company Profile

(Get Rating)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.